Latest Lucentis Stories
Study Did Not Meet Primary or Key Secondary Endpoints SAN DIEGO, May 20, 2015 /PRNewswire/ -- Lpath, Inc.
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Lucentis (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" market research
SAN DIEGO, March 16, 2015 /PRNewswire/ -- Gensignia Life Sciences, Inc., (Gensignia) a molecular diagnostics company specializing in microRNA (miRNA) signatures as cancer diagnostic
In patients with moderate or worse vision loss at baseline, those treated with EYLEA gained, on average, an additional full line or more on an eye chart when compared to those treated with alternative
SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ -- Pfenex Inc.
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.